GT Biopharma develops clinical-stage immuno-oncology therapeutics based on its proprietary TriKE® natural killer cell engager platform. News around GTBP focuses on candidate-specific development updates for GTB-3650, a TriKE® program for relapsed or refractory CD33-expressing hematologic malignancies, and GTB-5550, a B7-H3-targeted TriKE® program for solid tumors known to express B7-H3.
Company updates also cover FDA investigational new drug activity, Phase 1 trial enrollment and safety-review disclosures, R&D spending, liquidity commentary and periodic financial results. GT Biopharma also issues investor-conference announcements as it presents its NK cell engager strategy and clinical pipeline to the capital markets.
GT Biopharma (NASDAQ: GTBP) was selected for an oral presentation at the SITC annual meeting on November 6, 2026. The presentation, titled “Inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK cell immunotherapy,” will be delivered by Paarth Dodhiawala of the University of Minnesota Medical School.
Abstract 655 is scheduled for 3:05–3:20 PM MT in the session “Combination Therapies Involving Cell Therapy.” The Society for Immunotherapy of Cancer meeting runs November 4–8, 2026, in Phoenix, Arizona.
GT Biopharma (GTBP) received FDA clearance for a new IND to study GTB-5550, a B7-H3-targeted TriKE NK cell engager, in multiple myeloma under an investigator sponsored Phase 1a/1b trial. Initiation of this trial in later-line multiple myeloma patients is contingent on timing and receipt of non-dilutive grant funding. A separate Phase 1 dose-escalation basket trial of GTB-5550 in solid tumor patients is actively enrolling, with an update expected in Q4 2026. The company reports an unaudited pro forma cash balance of approximately $11 million as of September 15, 2026, which it anticipates will fund operations into Q3 2027.
GT Biopharma (GTBP) will host a live webinar on the development of its TriKE® natural killer (NK) cell engager platform for cancer treatment on September 11, 2026, at 2:00 p.m. Eastern Time. Executive Chairman and CEO Michael Breen and Consulting Senior Medical Director Dr. Jeffrey Miller will discuss clinical progress in blood cancers and solid tumors, dose-escalation insights, competitive positioning, and upcoming milestones. A replay will be available on gtbiopharma.com after the event.
GT Biopharma (NASDAQ: GTBP) reported second quarter 2026 results and clinical progress for its TriKE® NK cell engager platform. Cash and equivalents were approximately $5.1 million at June 30, 2026, which the company anticipates will fund operations through Q4 2026. Net loss was about $4.5 million, sharply lower than the $30.2 million net loss in Q2 2025, mainly due to the absence of a non‑cash, non‑recurring $28.7 million Greenshoe Rights liability recognized in the prior-year quarter.
R&D expenses rose to $1.1 million from $0.4 million, and SG&A expenses increased to $3.4 million from $1.1 million, driving a higher operating loss of $4.5 million. Clinically, GT Biopharma continues Phase 1 dose escalation for GTB-3650 in CD33-positive hematologic cancers and has initiated a Phase 1 basket trial for GTB-5550 in B7-H3-positive solid tumors, with data updates for both programs anticipated in the second half of 2026.
GT Biopharma (NASDAQ: GTBP) outlined expanded use of AI-based tools across its discovery pipeline for tumor-targeting engagers and multi-domain proteins. These initiatives aim to reduce trial-and-error work, shorten development timelines, cut costs, and improve candidate binding and functional activity, supporting advancement into potential pre-IND programs in 2027.
GT Biopharma (NASDAQ:GTBP) reported results for the quarter ended March 31, 2026 and provided pipeline updates. Cash and equivalents were about $9 million, expected to fund operations through Q4 2026.
Phase 1 trials of GTB-3650 for CD33+ leukemias and GTB-5550 for B7-H3+ solid tumors are ongoing, with additional data updates anticipated in 2H 2026.
For the comparable 2025 period, R&D expenses declined to about $0.4 million from $1.1 million, while SG&A (ex-stock comp) rose to about $2.4 million from $0.8 million. Net loss increased to approximately $2.8 million from $0.8 million.
GT Biopharma (NASDAQ: GTBP) dosed the first patient in its Phase 1 dose-escalation basket trial of GTB-5550, a B7-H3-targeted TriKE NK cell engager for solid tumors.
The study includes a Phase 1a prostate cancer-focused dose escalation followed by a Phase 1b expansion across up to seven B7-H3–positive tumor types, using subcutaneous dosing, with updates anticipated in 2H 2026.
GT Biopharma (NASDAQ: GTBP) announced that Michael Breen, Executive Chairman and CEO, will participate in the 38th Annual Roth Conference in Laguna Niguel, CA, March 22-24, 2026.
Presentation is scheduled for Tuesday, March 24, 2026 at 1:30 PM PDT; the company will also be available for one-on-one investor meetings by contacting a Roth representative.
GT Biopharma (NASDAQ: GTBP) reported full year 2025 results and operational updates on March 2, 2026. The company had $7M cash as of Dec 31, 2025 and an unaudited proforma cash balance of $9M as of Jan 31, 2026, anticipated to fund operations through Q4 2026.
GTBP is enrolling a Phase 1 dose‑escalation trial of GTB-3650 and plans to initiate a Phase 1 basket trial of GTB-5550 mid‑2026; next pipeline update expected in Q3 2026.
GT Biopharma (NASDAQ: GTBP) announced that Michael Breen, Executive Chairman and CEO, will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5, 2026 in Toronto.
Format includes a presentation, panel discussion and one-on-one investor meetings; the company will be available for 1x1 meetings throughout the day (8:00 AM–5:00 PM EDT).